416 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years

被引：0

作者：

Beck, Lisa A. ^{[1
]}

Bissonnette, Robert ^{[2
]}

Deleuran, Mette ^{[3
]}

Nakahara, Takeshi ^{[4
]}

Galus, Ryszard ^{[5
]}

Khokhar, Faisal A. ^{[6
]}

Coleman, Anna ^{[7
]}

Gherardi, Guy ^{[8
]}

Xiao, Jing ^{[6
]}

Dingman, Robert ^{[6
]}

Xu, Christine ^{[9
]}

Avetisova, Elena ^{[6
]}

Dubost-Brama, Ariane ^{[10
]}

Shabbir, Arsalan ^{[6
]}

机构：

[1] Univ Rochester, Med Ctr, Rochester, NY USA

[2] Innovaderm Res, Montreal, PQ, Canada

[3] Aarhus Univ Hosp, Aarhus, Denmark

[4] Kyushu Univ, Fukuoka, Japan

[5] Med Univ Warsaw, Warsaw, Poland

[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[7] Regeneron Pharmaceut Inc, Dublin, Ireland

[8] Sanofi, Reading, England

[9] Sanofi, Bridgewater, NJ USA

[10] Sanofi, Chilly Mazarin, France

来源：

关键词：

efficacy; safety; atopic dermatitis; open-label extension; adult;

D O I：

10.1093/bjd/ljad162.036

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

416

引用

页数：2